These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1885750)

  • 1. Cross-reactive antibodies induced by a monovalent influenza B virus vaccine.
    Levandowski RA; Gross PA; Weksler M; Staton E; Williams MS; Bonelli J
    J Clin Microbiol; 1991 Jul; 29(7):1530-2. PubMed ID: 1885750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [DEVELOPMENT OF THE QUADRIVALENT LIVE ATTENUATED INFLUENZA VACCINE INCLUDING TWO INFLUENZA B LINEAGES--VICTORIA AND YAMAGATA].
    Desheva YA; Smolonogina TA; Doroshenko EM; Rudenko LG
    Vopr Virusol; 2016; 61(1):16-20. PubMed ID: 27145595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
    de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
    Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to influenza B viruses in immunologically unprimed children.
    Levandowski RA; Regnery HL; Staton E; Burgess BG; Williams MS; Groothuis JR
    Pediatrics; 1991 Nov; 88(5):1031-6. PubMed ID: 1945607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
    Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
    J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP; Robertson CA; Talbot HK; Decker MD
    Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses.
    Carlock MA; Ingram JG; Clutter EF; Cecil NC; Ramgopal M; Zimmerman RK; Warren W; Kleanthous H; Ross TM
    Hum Vaccin Immunother; 2019; 15(9):2030-2043. PubMed ID: 31291153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?
    Tan J; Asthagiri Arunkumar G; Krammer F
    Curr Opin Immunol; 2018 Aug; 53():45-50. PubMed ID: 29677684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
    Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
    mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination.
    Brokstad KA; Cox RJ; Major D; Wood JM; Haaheim LR
    Vaccine; 1995 Nov; 13(16):1522-8. PubMed ID: 8578836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL; Levin MJ; Block SL; Belshe RB; Ambrose CS; Falloon J
    Expert Rev Vaccines; 2012 Nov; 11(11):1293-303. PubMed ID: 23151111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-mismatched influenza B/Yamagata lineage viruses in Cuba, 2012-2013 season.
    Arencibia A; Piñón A; Acosta B; Fernandez L; Muné M; Valdés O; Savón C; Oropesa S; Gonzalez G; Roque R; Gonzalez G; Hernández B; Alfonso JM
    Infect Genet Evol; 2018 Mar; 58():110-114. PubMed ID: 29229320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.
    Lee JH; Cho HK; Kim KH; Lee J; Kim YJ; Eun BW; Kim NH; Kim DH; Jo DS; Kim HM; Kim YK
    J Korean Med Sci; 2019 Dec; 34(46):e279. PubMed ID: 31779056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: Implications for vaccine composition strategy.
    Paiva TM; Benega MA; Silva DB; Santos KC; Cruz AS; Hortenci MF; Barbieri MT; Monteiro MM; Barbosa HA; Carvalhanas TR
    J Med Virol; 2013 Nov; 85(11):1983-9. PubMed ID: 23926069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three Types of Broadly Reacting Antibodies against Influenza B Viruses Induced by Vaccination with Seasonal Influenza Viruses.
    Hirano D; Ohshima N; Kubota-Koketsu R; Yamasaki A; Kurosawa G; Okuno Y; Yoshida S; Kurosawa Y
    J Immunol Res; 2018; 2018():7251793. PubMed ID: 29854845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.